Evaluating treatment outcomes for esophageal cancer
Treatment Outcomes of Esophageal Cancer
University of California, San Francisco · NCT05177393
This study looks at how well different treatments for esophageal cancer work and how they affect patients' lives across several locations in Africa.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 2476 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | University of California, San Francisco (other) |
| Drugs / interventions | radiation |
| Locations | 6 sites (Bomet and 5 other locations) |
| Trial ID | NCT05177393 on ClinicalTrials.gov |
What this trial studies
This observational study aims to assess the effectiveness of various treatment strategies for esophageal cancer across multiple sites in the African Esophageal Cancer Consortium. Researchers will collect data on treatment types, including chemotherapy, radiation, and surgical options, while also evaluating patient-reported outcomes and overall survival rates. The study will involve patients diagnosed with esophageal cancer, who will be monitored for their treatment responses and quality of life during and after therapy.
Who should consider this trial
Good fit: Ideal candidates include adults aged 18 and older with a confirmed or presumptive diagnosis of esophageal cancer.
Not a fit: Patients who are unable to provide informed consent will not benefit from this study.
Why it matters
Potential benefit: If successful, this study could provide valuable insights into the most effective treatment options for esophageal cancer, improving patient outcomes and quality of life.
How similar studies have performed: Other studies have shown success in evaluating treatment outcomes for esophageal cancer, but this specific approach within the African context is relatively novel.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Participants with histopathologically confirmed or presumptive clinical diagnosis of EC. For patients who do not have histopathologically confirmed disease, presumptive clinical diagnosis may be based upon barium swallow or endoscopy without biopsy. * Age 18 years of age or older; Exclusion Criteria: * Unable to provide informed consent
Where this trial is running
Bomet and 5 other locations
- Tenwek Hospital — Bomet, Kenya (RECRUITING)
- Moi Teaching and Referral Hospital — Eldoret, Kenya (RECRUITING)
- Kamuzu Central Hospital — Lilongwe, Malawi (RECRUITING)
- Muhimbili National Hospital — Dar es Salaam, Tanzania (RECRUITING)
- Ocean Road Cancer Institute — Dar es Salaam, Tanzania (RECRUITING)
- Kilimanjaro Christian Medical Centre — Moshi, Tanzania (RECRUITING)
Study contacts
- Principal investigator: Geoffrey Buckle, MD, MPH — University of California, San Francisco
- Study coordinator: Geoffrey Buckle, MD, MPH
- Email: geoffrey.buckle@ucsf.edu
- Phone: (415) 476-1528
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Esophageal Cancer, Treatment outcomes, Quality of life, Comparative effectiveness, Palliation